Search hospitals > Texas > Arlington
Texas Clinical Research Institute
Claim this profileArlington, Texas 76012
Global Leader in Non-alcoholic Fatty Liver Disease
Global Leader in Fatty Liver Disease
Conducts research for Hepatitis C
Conducts research for Liver Cirrhosis
Conducts research for Fibrosis
90 reported clinical trials
2 medical researchers
Summary
Texas Clinical Research Institute is a medical facility located in Arlington, Texas. This center is recognized for care of Non-alcoholic Fatty Liver Disease, Fatty Liver Disease, Hepatitis C, Liver Cirrhosis, Fibrosis and other specialties. Texas Clinical Research Institute is involved with conducting 90 clinical trials across 40 conditions. There are 2 research doctors associated with this hospital, such as Reem Ghalib, MD and M. Tarek Al-Assi, MD.Area of expertise
1Non-alcoholic Fatty Liver Disease
Global LeaderStage I
Stage II
stage 2
2Fatty Liver Disease
Global LeaderStage I
Stage II
stage 2
Top PIs
Reem Ghalib, MDTexas Clinical Research Institute, LLC4 years of reported clinical research
Studies Non-alcoholic Fatty Liver Disease
Studies Fatty Liver Disease
5 reported clinical trials
8 drugs studied
M. Tarek Al-Assi, MDTexas Clinical Research Institute1 year of reported clinical research
Studies Ulcerative Colitis
Studies Inflammatory Bowel Disease
4 reported clinical trials
4 drugs studied
Clinical Trials running at Texas Clinical Research Institute
Ulcerative Colitis
Non-alcoholic Fatty Liver Disease
Liver Cirrhosis
Type 2 Diabetes
Inflammatory Bowel Disease
Ulcer
Nonalcoholic Steatohepatitis
Fatty Liver Disease
Cholangitis
Primary Biliary Cirrhosis
ABX464 Maintenance Therapy
for Ulcerative Colitis
This is a multicenter, randomized study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once daily (QD) as maintenance therapy in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors]. This study is the maintenance phase of both previous induction studies ABX464-105 and ABX464-106. All eligible subjects who have completed either one of the induction studies above mentioned, will be given the opportunity to take part in the present ABX464-107 maintenance study and will be randomized to either a double blind, placebo-controlled part (Part #1) or allocated to ABX464 50mg or 25mg open label treatment arms (Part #2) depending on their clinical response at the end of induction. This study consists of a 44-week treatment phase and a 28-days follow-up period consisting in the End of Study (EOS) visit.
Recruiting1 award Phase 3
ABX464
for Ulcerative Colitis
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies [corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)] and/or advanced therapies [biologics (TNF inhibitors, anti-integrins, anti-IL-23), and/or S1P receptor modulators, and/or JAK inhibitors].
Recruiting1 award Phase 36 criteria
PL-8177
for Ulcerative Colitis
The purpose of this study is to compare PL8177 (a melanocortin receptor agonist) to placebo (in a 3:1 ratio-meaning that for every 3 people that get the active drug, one will receive placebo). The study treatment will be for 8 weeks. The study will measure safety and the body's ability to handle PL8177 and look at the improvement and healing of the intestine after 8 weeks of treatment. The study will include adult males and nonpregnant, nonlactating females with acute Ulcerative Colitis (UC).
Recruiting0 awards Phase 27 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Texas Clinical Research Institute?
Texas Clinical Research Institute is a medical facility located in Arlington, Texas. This center is recognized for care of Non-alcoholic Fatty Liver Disease, Fatty Liver Disease, Hepatitis C, Liver Cirrhosis, Fibrosis and other specialties. Texas Clinical Research Institute is involved with conducting 90 clinical trials across 40 conditions. There are 2 research doctors associated with this hospital, such as Reem Ghalib, MD and M. Tarek Al-Assi, MD.